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sional group was more modest; they more often consulted their GP 
(90% had consulted during the last 12 months); 42% had consulted a 
psychotherapist or taken psychotropic drugs; 73% were afraid of cancer 
in general; 59% had a family history of cancer (33% among the close 
circle); and 66% were in favour of cancer screening. Of the participat-
ing GPs, 63% recommended lung cancer screening to their patients 
with no speciﬁc history of cancer (systemically for 4% of GPs). 
Conclusion: Implementation of individual screening for lung cancer 
using chest radiography concerns only 6% of the French population 
aged 40 to 75 years. This reﬂects the lack of speciﬁc incentive to per-
form this screening, as opposed to what is observed for breast cancer 
(93% of French women aged 50 to 74 years already underwent at least 
one screening mammography) (1). The subjects performing individual 
screening for lung cancer are most often those with heightened aware-
ness due to a history of lung cancer in their close circle while they are 
or were smokers themselves. 
(1) Pivot X et al. Cancer screening tests in France: ﬁrst results of EDIFICE study. ASCO 
2006, Atlanta; Abst 6092. 
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The Epidermal growth factor receptor (EGFR) is a tyrosine kinase 
receptor that mediates the intracellular effects of growth factors, 
such as EGF, transforming growth factor α and neuregulins, and thus 
plays an important role in the development and progression of cancer. 
Polymorphisms in the EGFR gene may inﬂuence EGFR production 
and/or activity, thereby modulating susceptibility to lung cancer. To 
test this hypothesis, we ﬁrst examined the frequencies of 39 candidate 
polymorphisms in the EGFR gene in 27 healthy Korean individuals. 
After then, we selected ﬁve polymorphisms (127378C>T, 142285G>A, 
162093G>A, 181946C>T and 187114T>C) that have variant allele 
frequencies greater than 10%, and genotyped the ﬁve polymorphisms 
by a PCR-RFLP assay in 582 lung cancer patients and in 582 healthy 
controls that were frequency-matched for age and gender. Of the 5 
polymorphisms studied, the 181946C>T genotype distribution was sig-
niﬁcantly different between the cases and controls (P = 0.04), with the 
frequency of the variant T allele being signiﬁcantly lower in the cases 
than in the controls (35.4% vs 40.3%, P = 0.01). Compared with the 
181946 CC + CT genotype, the 181946 TT genotype was associated 
with a signiﬁcantly decreased risk of lung cancer (adjusted OR = 0.63, 
95% CI = 0.45-0.88, P = 0.007). When the analyses were stratiﬁed by 
smoking status, the protective effect of the TT genotype was statisti-
cally signiﬁcant in ever-smokers (adjusted OR = 0.59, 95% CI = 0.41-
0.86, P = 0.007), but not in never-smokers (adjusted OR = 0.89, 95% 
CI = 0.45-1.75, P = 0.73; P = 0.08, test for homogeneity). Consistent 
with the results of the genotyping analysis, the 127378C/142285G/
162093G/181946C/187114T (CGGCT) haplotype with the 181946C 
allele was associated with a signiﬁcantly increased risk of lung cancer 
compared to the 127378C/142285G/162093G/181946T/187114T (CG-
GTT) haplotype carrying the 181946T allele (adjusted OR = 1.49, 95% 
CI = 1.09-2.05, P = 0.013 and Bonferroni corrected P-value = 0.039). 
These results suggest that the EGFR polymorphisms, particularly the 
181945C>T polymorphism, could be used as markers for the genetic 
susceptibility to lung cancer.
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The epidermal growth factor receptor (EGFR), and its family members 
play an important role in the development and progression of lung can-
cers. It has been reported that somatic mutations in the tyrosine kinase 
domain of the EGFR or ERBB2 genes occur in a subset of patients with 
lung cancer. We searched for mutations of the EGFR, ERBB2 and K-
ras genes in surgically resected non-small cell lung cancers (NSCLCs) 
to determine the prevalence of these mutations in Korean lung cancer 
patients. In addition, we examined the relationship between the muta-
tions and clinico-pathologic features of lung cancers. Mutations of the 
EGFR, ERBB2 and K-ras genes were determined by PCR-based direct 
sequencing in 115 surgically resected non-small cell lung cancers. 
EGFR mutations were present in 20 patients (17.4%). All EGFR 
mutations were found in adenocarcinomas (20 of 55 adenocarcinomas, 
36.4%). The ERBB2 mutation was found in one adenocarcinoma of the 
115 NSCLCs (overall 0.9%; and 1.8% of 55 adenocarcinomas). K-ras 
mutations were found in six (5.2%) of the 115 NSCLCs [two (3.3%) of 
60 squamous cell carcinomas; and four (7.3%) of 55 adenocarcinomas]. 
EGFR mutations in adenocarcinomas were more frequent in females (P 
= 0.02) and never-smokers (P = 0.004). EGFR mutations in adenocar-
cinomas were not associated with pathologic stage in never-smokers, 
whereas they were more frequent in pathologic stage II-IV than in stage 
I in ever-smokers (P = 0.01). Of the 55 adenocarcinomas, 25 (45.5%) 
had mutations of either one of the three genes, and EGFR mutations 
were never found in tumors with ERBB2 or K-ras mutations. These 
ﬁndings suggest that the EGFR mutation frequently occurs in Korean 
lung cancer patients, and that the ERBB2 mutation is rare. Further 
studies are needed to investigate the role of EGFR mutations in the 
carcinogenesis of adenocarcinoma among smokers.
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